GlassScriptPhysician profile
Mahmoud Farhoud
NPI 1114215852
$4,012.63
in general payments reported to CMS, 2019-2025
27 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $234 · 2021: $284 · 2022: $680 · 2023: $716 · 2024: $1,336 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880 · Travel and Lodging: $627 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,879.53 |
| Travel and Lodging | $627.24 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,182.49 | 2020-2025 | Resonate El Icd Vr, Cds - Other, Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $477.18 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Pfizer INC. | $359.95 | 2022-2025 | |
| Amgen INC. | $355.58 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $243.50 | 2020-2025 | |
| Lexicon Pharmaceuticals, INC. | $178.57 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $150.06 | 2023-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $137.19 | 2021-2024 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $129.09 | 2020-2024 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $109.05 | 2020-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $108.29 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $83.64 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $62.54 | 2019 | |
| Alnylam Pharmaceuticals INC. | $61.27 | 2020 | |
| Cardiovascular Systems INC. | $55.40 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.17 | 2021-2023 | Lifevest |
| Medtronic Vascular, INC. | $45.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.94 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $31.49 | 2022-2025 | Uptravi |
| Chiesi USA, INC. | $28.11 | 2025 | Kengreal |
| Atricure, INC. | $25.70 | 2023 | |
| Esperion Therapeutics, INC. | $20.24 | 2023 | Nexletol |
| Cvrx, INC. | $18.13 | 2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.00 | 2019 | |
| American Regent | $16.19 | 2023 | Injectafer |
| Medtronic, INC. | $11.07 | 2021 | |
| Amarin Pharma, INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Farhoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.